Sanofi India Share Price

Sanofi India

CMP as on 20-May-22 15:40

₹ 6,579.15
12.15 0.19%

Open

₹ 6,640.00

Turnover (lac)

₹ 436

Prev. Close

₹ 6,567.00

Day's Vol (shares)

₹ 6,634

Day's Range (₹)

₹ 6,568.00
₹ 6,649.85

CMP as on20-May-22 15:25

₹ 6,580.00
3.35 0.05%

Open

₹ 6,606.15

Turnover (lac)

₹ 22

Prev. Close

₹ 6,576.65

Day's Vol (shares)

₹ 604

Day's Range

₹ 6,563.00
₹ 6,654.00

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 07-Apr-2022 - -
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/04/2022 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday 26th April 2022; inter alia to consider the unaudited financial results for the quarter ended 31st March 2022 (Q1). Further to our intimation on 28th March 2022 this is to inform you that as per the Sanofi India Limited- Code of Conduct to Regulate Monitor and Report Trading by Designated Persons the trading window of the Company which was closed from 1st April 2022 for publication of financial results of the Company for the quarter ended 31st March 2022 shall remain closed up to Thursday 28th April 2022 (inclusive of both days). We refer to our letter dated 7th April 2022 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 12.00 noon and concluded at 2.15 p.m. The Board approved unaudited financial results for the quarter ended 31st March 2022. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter ended 31st March 2022 approved at this Meeting along with a copy of the Limited Review Report for your information. Please take the above information on record (As Per BSE Announcement Dated on 26.04.2022) In terms of Regulation 30 of the SEBI Listing Regulations, we hereby inform that the Board of Directors at its meeting held on 26th April 2022, approved conducting of Postal Ballot for seeking the approval of members for appointment of Mr. Rodolfo Hrosz as Managing Director of the Company w.e.f 1st June 2022 by passing an Ordinary Resolution. The Board of Directors have also appointed Mr. Makarand M. Joshi, Partner or failing him Ms. Kumudini Bhalerao, Partner at M/s Makarand M. Joshi & Co., Practicing Company Secretaries, who have given the consent to act as the Scrutinizer, for conducting the Postal Ballot process. The Company shall further intimate the Stock Exchanges on dispatch of the Postal Ballot notice. The Calendar of Events for the proposed postal ballot process is attached for your reference (As Per BSE Announcement Dated on 27.04.2022)
Board Meeting - 18-Apr-2022 - -
The Board of Directors of the Company at its Meeting held today, based on recommendation of the Nomination and Remuneration Committee approved the appointment of Mr. Rodolfo Hrosz as the Additional Director of the Company with effect from 1st June 2022 and as the Managing Director for a period of three years with effect from 1st June, 2022, subject to approval of the shareholders and other regulatory approvals, as may be required. Mr. Rodolfo Hrosz is not related to any Director of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other Authority. The Press Release in this regard, is enclosed. Please take the above information on record.
Board Meeting - 07-Feb-2022 - -
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2022 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the meeting of the Board of Directors of the Company will be held on Wednesday 23rd February 2022; inter alia to consider and: approve the audited accounts for the quarter and the year ended 31st December 2021. recommend final dividend for the financial year ended 31st December 2021. You are requested to take the above on record. Further to our intimation on 27th December 2021 this is to inform you that as per the Sanofi India Limited- Code of Conduct to Regulate Monitor and Report Trading by Designated Persons the trading window of the Company which was closed from January 1 2022 for publication of financial results of the Company for the quarter and the year ended 31st December 2021 shall remain closed up to Friday 25th February 2022 (inclusive of both days). We refer to our letter dated 7th February 2022 informing you of our Board Meeting that was scheduled today. The meeting of Board of Directors commenced at 2.30 p.m. and concluded at 6.15 p.m. The Board approved audited financial results for the quarter and year ended 31st December 2021. Sanofi India Ltd We enclose a copy of the auditors report and audited financial results of the Company for the quarter and year ended 31st December 2021 along with statement of assets and liabilities as on that date and statement of cashflows for the year ended 31st December 2021 along with press release as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information. The Board of Directors of the Company at its Meeting held today, subject to the approval of the shareholders at the 66th Annual General Meeting, recommended the re-appointment of M/s. Price Waterhouse & Co. Chartered Accountants LLP as Statutory Auditors for a period of five years, from the conclusion of the Sixty-sixth AGM, until the conclusion of the seventy-first AGM of the Company. The brief profile of M/s. Price Waterhouse & Co. Chartered Accountants is enclosed: We refer to our letter dated 7th February 2022 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 2.30 p.m. and concluded a 6.15 p.m. The following items were considered and approved: 1. Recommendation for payment of a final dividend of Rs.181 per equity share of Rs. 10 each for the year ended 31st December 2021 and a special dividend of Rs. 309 per equity share of Rs.10 each for the year ended 31st December 2021, after considering the slump sale and transfer of Companys nutraceuticals business during the year and reviewing the cash requirements for the Companys operations. 2. Closure of Register of Members and Share Transfer Books from for determining the eligibility of shareholders for payment of the final dividend and the special dividend. (As Per BSE Announcement Dated 23.02.2022)
Board Meeting - 13-Oct-2021 - -
Quarterly Results We refer to our letter dated 13th October 2021 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 1.30 p.m. and concluded at 04.00 p.m. The Board approved unaudited financial results for the quarter and nine months ended 30th September 2021. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter and nine months ended 30th September 2021 approved at this Meeting along with a copy of the Limited Review Report duly signed by the Auditors of the Company. (As per BSE Announcement Dated on 26/10/2021) As required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at its meeting held on 26th October 2021, approved appointment of Ms. Radhika Shah as Company Secretary and Key Managerial Personnel with effect from 1st November 2021. Pursuant to Regulation 6 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ms. Radhika Shah will also be the Compliance Officer with effect from 1st November 2021 in place of Mr. Vaibhav Karandikar. Detailed announcement is enclosed. Please take the above information on record. (As Per BSE announcement Dated on 27.10.2021)
Board Meeting - 12-Jul-2021 - -
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, 27th July 2021; inter alia to consider the unaudited financial results for the quarter and half year ended 30th June 2021 (Q2). We refer to our letter dated 12th July 2021 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 11.30 a.m. and concluded at 1.45 p.m. The Board approved unaudited financial results for the quarter and half year ended 30th June 2021. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter and half year ended 30th June 2021 approved at this Meeting including the Statement of Assets and Liabilities as on that date and the Statement of Cash Flow for the half year ended 30th June 2021 along with a copy of the Limited Review Report duly signed by the Auditors of the Company. (As per BSE Announcement Dated on 27/7/2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity